Activation of G-proteins in brain by endogenous and exogenous cannabinoids

Journal Title: The AAPS Journal - Year 2006, Vol 8, Issue 1

Abstract

The biological response to cannabinoid agonist begins when the agonist-bound receptor activates G-protein Gα subunits, thus initiating a cascade of signal transduction pathways. For this reason, information about cannabinoid receptors/G-protein coupling is critical to understand both the acute and chronic actions of cannabinoids. This review focuses on these mechanisms, predominantly examining the ability of cannabinoid agonists to activate G-proteins in brain with agonist-stimulated [35S]guanylyl-5′-O-(γ-thio)-triphosphate ([35S]GTPγS) binding. Acute efficacies of cannabinoid agonists at the level of G-protein activation depend not only on the ability of the agonist to induce a high affinity state in Gα for GTP, but also to induce a low affinity for GDP. When several agonists are compared, it is clear that cannabinoid agonists differ considerably in their efficacy. Both WIN 55212-2 and levonantradol are full agonists, while Δ9 is a weak partial agonist. Of interest, anandamide and its stable analog methanand amide are partial agonists. Chronic treatment in vivo with cannabinoids produces significant tolerance to the physiological and behavioral effects of these drugs, and several studies have shown that this is accompanied by a significant loss in the ability of cannabinoid receptors to couple to G-proteins in brain. These effects vary across different brain regions and are usually (but not always) accompanied by loss of cannabinoid receptor binding. Although the relationship between cannabinoid receptor desensitization and tolerance has not yet been established, these mechanisms may represent events that lead to a loss of cannabinoid agonist response and development of tolerance.

Authors and Affiliations

Steven R. Childers

Keywords

Related Articles

In Vitro, Pharmacokinetic, Pharmacodynamic, and Safety Comparisons of Single and Combined Administration of Tiotropium and Salmeterol in COPD Patients Using Different Dry Powder Inhalers

The online version of this article (doi:10.1208/s12248-015-9751-7) contains supplementary material, which is available to authorized users.

Estimation of Biliary Excretion of Foreign Compounds Using Properties of Molecular Structure

The online version of this article (doi:10.1208/s12248-013-9541-z) contains supplementary material, which is available to authorized users.

Evaluation of the Biological Properties and the Enzymatic Stability of Glycosylated Luteinizing Hormone-Releasing Hormone Analogs

The online version of this article (doi:10.1208/s12248-015-9769-x) contains supplementary material, which is available to authorized users.

Retraction note to: Recent advances for the treatment of cocaine abuse: central nervous system immunopharmacotherapy

The online version of the original article can be found at http://dx.doi.org10.1208/aapsj070359.

Critical ligand binding reagent preparation/selection: When specificity depends on reagents

Throughout the life cycle of biopharmaceutical products, bioanalytical support is provided using ligand binding assays to measure the drug product for pharmacokinetic, pharmacodynamic, and immunogenicity studies. The spe...

Download PDF file
  • EP ID EP681644
  • DOI  10.1208/aapsj080113
  • Views 78
  • Downloads 0

How To Cite

Steven R. Childers (2006). Activation of G-proteins in brain by endogenous and exogenous cannabinoids. The AAPS Journal, 8(1), -. https://europub.co.uk/articles/-A-681644